A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer
 and bone metastases
Inclusion Criteria:

 -  Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who
 have not received any bisphosphonates in the 12 months prior to enrollment

 -  18 years old and over

 Exclusion Criteria:

 -  Plan to be on cytotoxic or biologic therapy during study

 -  Active dental problems

 -  Active heart complications

 -  Active infection

 -  Patients with moderate to severe swelling due to fluid

 Other protocol-defined inclusion/exclusion criteria may apply